ERBB2 and gastric cancer: Trastuzumab is one of the approved anti-HER2 therapy in combination with chemotherapy for patients with advanced gastric cancer, but its antitumor efficacies are less favorable due to insufficient cell sensitivity and drug resistance28,29.